Tue, May 13, 7:22 PM (30 days ago)
**Protagenic Therapeutics, Inc. (PTIX) Q1 2025 Financial Summary** Protagenic Therapeutics, Inc. (PTIX) reported a net loss of $1,440,005 for Q1 2025, compared to a net loss of $1,724,294 in Q1 2024. The company's total operating and administrative expenses decreased to $1,448,108 from $1,738,359 year-over-year, primarily due to a $580,374 reduction in research and development expenses. However, general and administrative expenses increased by $290,123, mainly due to higher stock compensation and legal costs. **Key Financial Metrics:** - **Revenue:** No revenue was generated in Q1 2025. - **Gross Margin:** Not applicable due to zero revenue. - **Operating Margin:** -147.4% (Loss from operations / Total revenue) - **Net Margin:** -147.4% (Net loss / Total revenue) - **Cash Flow:** Net cash used in operating activities was $1,068,017, an improvement from $1,659,185 in Q1 2024. - **Cash Position:** Ended the quarter with $872,960 in cash, down from $1,838,469 at the end of 2024. - **Shareholders' Equity:** Negative $88,329, compared to positive $1,013,154 at the end of 2024. **Trends and Uncertainties:** - PTIX continues to face significant financial challenges, with substantial recurring losses and negative cash flows from operations. - The company's going concern status is uncertain, as it may not have sufficient resources to fund operations past twelve months from the date of the financial statements. - PTIX is focused on its lead compound, PT00114, and is conducting a Phase I/IIa clinical trial. However, the outcome of this trial and the company's ability to secure additional funding are significant uncertainties. **Future Operations Impact:** - PTIX plans to continue its clinical trials and product development activities, seek regulatory approvals, and explore partnerships or collaborations. - The company may need to obtain additional debt or equity financing to support its operations and development programs. - PTIX is subject to various risks and uncertainties, including those related to its clinical trials, regulatory approvals, intellectual property, and market competition. **Stock Performance:** - PTIX's stock price has been volatile, and the company has been subject to delisting concerns due to its low stock price. - On May 5, 2025, PTIX effectuated a 1-for-14 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.